ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Phosphorylation-Dependent Stabilization of Collaborator of ARF (CARF) Suppresses Lymphoma Cell Proliferation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CEBPG demonstrates oncogene functions and modulates the expression of genes involved in cervical cancer related pathways.Translational cancer research · 2026Article
- Phosphorylation-Dependent Stabilization of Collaborator of ARF (CARF) Suppresses Lymphoma Cell Proliferation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Uncontrolled cell proliferation drives tumorigenesis and malignant progression, making cell cycle regulation a promising strategy for cancer therapy. Phosphorylation plays pivotal roles in cancer initiation and metastasis by regulating the cancer-related proteins. Identifying key phosphorylation sites is essential for inhibiting tumor cell proliferation and optimizing therapy strategy. Here, this study reveals the strong association of oncogene Collaborator of ARF (CARF), a cell-division regulator interacting with p53, with prognosis and survival of lymphoma patients through pan-cancer analysis. In addition, this study finds that mammalian CARF shares homology with Kip-Related Protein6 (KRP6), a cell cycle inhibitor from higher plant Arabidopsis. KRP6 is regulated by casein kinase1 via phosphorylation at serines 75 and 109, which are conservative in CARF at serines 316 and 356. Systemic assays conducted with various B-cell lymphoma cell lines and a mouse xenograft model demonstrate that the non-phosphorylation variant of CARF inhibited cell proliferation and lymphoma formation more effectively than wild-type CARF, highlighting the crucial regulatory role of phosphorylation at these conserved sites in controlling B-cell lymphoma cell proliferation. A similar suppressive effect is observed with plant KRP6, suggesting a cross-species bioengineering application. These findings enlighten the application of phosphorylation-modified proteins as therapeutic targets in precise lymphoma treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.